The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that benefits of four fibrates such as: bezafibrate, ciprofibrate, fenofibrate and gemfibrozil continue outweigh their risk in treatment of people with blood lipid disorders. (bvsalud.org)
Having previously fast-tracked this paper to publication in summary form, we now expand on why cimetidine/famotidine (histamine type-2 receptor antagonists), dipyridamole (antiplatelet agent), fenofibrate/bezafibrate (cholesterol/triglyceride-lowering agents), and sildenafil (phosphodiesterase-5 inhibitor) are worth considering for patients with COVID-19 based on their antiviral, anti-inflammatory, renoprotective, cardioprotective, and anticoagulation properties. (jmir.org)
Having recently published a short summary of our thesis [ 2 ], the current paper expands on why cimetidine or famotidine (histamine type-2 receptor antagonists), dipyridamole (antiplatelet agent), fenofibrate or bezafibrate (cholesterol/triglycerides-lowering agents), and sildenafil (phosphodiesterase-5 inhibitor) are worth considering for patients with COVID-19. (jmir.org)
Mitochondrial4
In conclusion, lack of pRb results in MDS-like anemia with disrupted differentiation and impaired mitochondrial function at the orthochromatic erythroblast stage. (lu.se)
Treatment with Bezafibrate, a promoter of mitochondrial activity, reversed this increase. (lifespan.io)
Bezafibrate is getting a well-deserved trial for mitochondrial disease. (epiphanyasd.com)
5. Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. (ac.ir)
Findings1
Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. (cdc.gov)
Cholesterol1
Bezafibrate is an old drug to lower cholesterol. (epiphanyasd.com)
Treatment4
In mediation analysis, the association between bezafibrate treatment and cancer incidence was not sensitive to adjustment for on-trial lipid levels but was attenuated on adjustment for on-trial fibrinogen levels. (iucc.ac.il)
Conclusion: Bezafibrate treatment is associated with reduced risk of cancer among patients with CAD. (iucc.ac.il)
Conclusion UDCA and bezafibrate combined treatment is superior to UDCA alone in UDCA non-responders with regard to decreasing liver biochemistry markers, without any significant increase in side effects in patients with PBC. (annalsgastro.gr)
Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. (ac.ir)
Patients4
Objective: To evaluate the association between bezafibrate, a drug used to treat hypertriglyceridemia, and long-term cancer incidence in patients with coronary artery disease (CAD). (iucc.ac.il)
Patients randomized to receive 400 mg of bezafibrate (n=1486) or placebo (n=1494) daily for a median of 6.2 years (range, 4.7-7.6 years) were followed up for incidence of cancer through the Israeli National Cancer Registry and all-cause death through the Population Registry of the State of Israel until December 31, 2013. (iucc.ac.il)
Since some patients do not respond adequately to UDCA, other therapies, such as bezafibrate, have been developed. (annalsgastro.gr)
In this meta-analysis we evaluated the efficacy and safety of using both UDCA and bezafibrate in patients with an inadequate response to UDCA. (annalsgastro.gr)
Drug1
Bezafibrate, a blood lipid prescription drug, was found at a maximum concentration of 0.06 μg per liter and an average concentration of 0.035 μg per liter. (zavit.org.il)
Groups1
The hazard ratio for cancer in the bezafibrate vs placebo groups was 0.86 (95% CI, 0.74-0.99). (iucc.ac.il)
Study1
2729 [91.6%] men) who were free of cancer and were enrolled in the Bezafibrate Infarction Prevention study, a double-blind trial conducted between May 1, 1990, and January 31, 1993, in 18 cardiology departments in Israel. (iucc.ac.il)
Activation1
We recently reported that bezafibrate, a pan-agonist of PPARs, decreases body temperature late at night through hypothalamic neuropeptide Y (NPY) activation and others have shown that mice overexpressing FGF21 are prone to torpor. (nel.edu)
Gemfibrozil1
Among fibrates, gemfibrozil was most effective, though bezafibrate may significantly reduce the risk of MACE in populations with triglyceride levels of 200-300 mg/dL. (biomedcentral.com)
UDCA11
The aim of this study is to clarify the additive improvement induced by bezafibrate in patients refractory to UDCA. (medscape.com)
All patients were treated first for 6 months with UDCA, and then with bezafibrate, if their alkaline phosphatase (ALP) levels did not decrease more than 40% or within the normal range after 6 months' treatment with UDCA. (medscape.com)
Combination treatment of bezafibrate in addition to UDCA may be an effective treatment for PBC patients refractory to UDCA. (medscape.com)
[ 10 ] Several studies have reported that bezafibrate, alone or in combination with UDCA, effectively improves serum hepatobiliary enzyme activity. (medscape.com)
[ 14 ] However, the prevalence of patients refractory to UDCA and the additive effects of bezafibrate on UDCA have not been fully investigated. (medscape.com)
Therefore, we conducted a prospective study to clarify the prevalence of PBC patients refractory to UDCA and the additive effects of bezafibrate and UDCA in these patients. (medscape.com)
Our results showed that half of PBC patients achieved normal alkaline phosphatase (ALP) levels with UDCA, and that combined treatment with bezafibrate and UDCA effectively normalized serum hepatobiliary enzyme activity and immunoglobulin M (IgM) levels in patients refractory to UDCA, suggesting that this combination is an effective treatment for this group of patients. (medscape.com)
Since some patients do not respond adequately to UDCA, other therapies, such as bezafibrate, have been developed. (annalsgastro.gr)
In this meta-analysis we evaluated the efficacy and safety of using both UDCA and bezafibrate in patients with an inadequate response to UDCA. (annalsgastro.gr)
Methods We evaluated all randomized controlled trials comparing the combination of UDCA and bezafibrate with UDCA monotherapy. (annalsgastro.gr)
Conclusion UDCA and bezafibrate combined treatment is superior to UDCA alone in UDCA non-responders with regard to decreasing liver biochemistry markers, without any significant increase in side effects in patients with PBC. (annalsgastro.gr)
Acid5
[ 7-9 ] Bezafibrate, a fibric acid derivative, is commonly used as an anti-hyperlipidemic agent, and has been reported to improve serum hepatobiliary enzyme activity. (medscape.com)
To assess whether bezafibrate increases fatty acid oxidation (FAO) and lowers heart rate (HR) during exercise in patients with carnitine palmitoyltransferase (CPT) II and very long-chain acyl-CoA dehydrogenase (VLCAD) deficiencies. (nih.gov)
A Mendelian randomization study for drug repurposing reveals bezafibrate and fenofibric acid as potential osteoporosis treatments. (bvsalud.org)
Bezafibrate (BZF) and Fenofibric acid (FBA) act as PPARG agonists . (bvsalud.org)
Conclusion: A phytol-enriched diet may increase phytanic acid levels in the liver and brown adipocytes, thereby activating PPAR-α in these organs and ameliorating obesity-induced metabolic diseases. (nara-wu.ac.jp)
Patients4
Those in Group B were treated additionally with bezafibrate, and 12 patients (80%) achieved normal ALP and IgM levels within 12 months of commencement of therapy. (medscape.com)
reported that bezafibrate improves the histological progression in PBC patients. (medscape.com)
This was a 3-month, randomized, double-blind, crossover study of bezafibrate in patients with CPT II (n = 5) and VLCAD (n = 5) deficiencies. (nih.gov)
Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. (nih.gov)
Therapy2
Methods Diet-controlled Type 2 subjects (n = 9) were studied before and after 16 weeks of combined PPAR-gamma [pioglitazone (PIO), 45 mg daily] and PPAR-alpha [bezafibrate (BEZA), modified release 400 mg daily] agonist therapy. (ncl.ac.uk)
Conclusions Combined PIO and BEZA therapy in Type 2 diabetes does not decrease intrahepatic triglyceride content or postprandial endogenous glucose production. (ncl.ac.uk)
Authors1
Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. (cdc.gov)
Clear1
Much of the data are conflicting, and clear conclusions do not seem justified. (shengsci.com)
Potential1
In conclusion, we identified the 8 candidate biomarkers and potential key signaling pathways in cutaneous melanoma through comprehensive microarray analyses. (jcancer.org)